News Sentiment

KNSA sentiment intelligence

Kiniksa Pharmaceuticals Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 63.44 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

87/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-1.7% over one week, +22.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Kiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent Gains

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 87/100 classification
One-week reaction -1.7% Price digesting
Trend fit Trend active 22.3% over four weeks
Fair value 123.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 33
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 23
Market source 8
simplywall.st 4
MarketBeat 3
GuruFocus 3
Ad Hoc News 3
Minichart 3
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 6
Analyst action 5
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Stock Titan Direct company coverage

Performance share awards at Kiniksa (NASDAQ: KNSA) tied to KPL-387 FDA goals

Kiniksa Pharmaceuticals International's Chief Strategy Officer, Dhiraj H. Malkani, received various equity awards on July 1, 2026, including performance share units, performance share options, and restricted share units. The vesting of these performance-linked awards is contingen

Tone
Positive 62/100
Event
Market update
Published
07 Jul 2026 21:10
Source
Stock Titan
TradingView Direct company coverage

Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (BOATS:KNSA)

This article provides an overview of Kiniksa Pharmaceuticals International, plc (KNSA) stock, including its financial actuals and estimates. It details analyst forecasts, historical price data, upcoming earnings reports, and key financial metrics like revenue, net income, and EBI

Tone
Positive 70/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

KNSA/N Forecast — Price Target — Prediction for 2027

This article provides a forecast for Kiniksa Pharmaceuticals International, plc Class A (KNSA/N) stock, including analyst price targets and future predictions. It details financial metrics such as EPS, revenue, market capitalization, and upcoming earnings dates, along with histor

Tone
Positive 72/100
Event
Earnings
Published
25 Jun 2026 20:10
Source
TradingView
Stock Titan Direct company coverage

Kiniksa (KNSA) director receives RSUs and options in equity grants

Kiniksa Pharmaceuticals International, plc director Barry D. Quart reported exercising 2,799 vested Restricted Share Units (RSUs) and receiving new equity grants on May 29, 2026. These new grants include 2,026 RSUs and options for 12,158 Class A Ordinary Shares with an exercise p

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 14:39
Source
Stock Titan
Stock Titan Direct company coverage

Kiniksa (KNSA) awards RSUs and options to Baker-affiliated board representatives

Kiniksa Pharmaceuticals International, plc (KNSA) granted restricted share units (RSUs) and non-qualified share options to three Baker-affiliated directors, including Felix J. Baker. Each director received 2,026 RSUs and 12,158 share options with a strike price of $48.38, as comp

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 07:39
Source
Stock Titan
Stock Titan Direct company coverage

Kiniksa (KNSA) director Malley exercises RSUs and receives new option grant

Kiniksa Pharmaceuticals director Thomas Malley recently exercised 2,799 Restricted Share Units and received new grants, including 2,026 RSUs and a share option for 12,158 Class A Ordinary Shares, with an exercise price of $48.38 per share. These transactions, which occurred on Ma

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 02:40
Source
Stock Titan
Stock Titan Direct company coverage

Kiniksa (NASDAQ: KNSA) director exercises 2,799 RSUs and gets options on 12,158 shares

Kiniksa Pharmaceuticals director Tracey L. McCain exercised 2,799 Restricted Share Units (RSUs) converting them into Class A Ordinary Shares, increasing her direct holdings to 15,345 shares. She also received new grants of 2,026 RSUs and share options for 12,158 Class A Ordinary

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 00:39
Source
Stock Titan
Stock Titan Direct company coverage

Kiniksa Pharmaceuticals (KNSA) director gains shares and new equity awards

Kiniksa Pharmaceuticals director Cole G. Bradley reported exercising 2,799 Restricted Share Units (RSUs) into Class A Ordinary Shares, increasing his direct holdings to 15,345 shares. He also received new equity awards, including 2,026 RSUs and options on 12,158 Class A Ordinary

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 00:39
Source
Stock Titan